88 related articles for article (PubMed ID: 21093044)
1. Quantitative proteomic profiling of breast cancers using a multiplexed microfluidic platform for immunohistochemistry and immunocytochemistry.
Kim MS; Kwon S; Kim T; Lee ES; Park JK
Biomaterials; 2011 Feb; 32(5):1396-403. PubMed ID: 21093044
[TBL] [Abstract][Full Text] [Related]
2. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer diagnostics using microfluidic multiplexed immunohistochemistry.
Kim MS; Kwon S; Park JK
Methods Mol Biol; 2013; 949():349-64. PubMed ID: 23329453
[TBL] [Abstract][Full Text] [Related]
4. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer diagnosis using a microfluidic multiplexed immunohistochemistry platform.
Kim MS; Kim T; Kong SY; Kwon S; Bae CY; Choi J; Kim CH; Lee ES; Park JK
PLoS One; 2010 May; 5(5):e10441. PubMed ID: 20454672
[TBL] [Abstract][Full Text] [Related]
6. Novel breast cancer biomarkers identified by integrative proteomic and gene expression mapping.
Ou K; Yu K; Kesuma D; Hooi M; Huang N; Chen W; Lee SY; Goh XP; Tan LK; Liu J; Soon SY; Bin Abdul Rashid S; Putti TC; Jikuya H; Ichikawa T; Nishimura O; Salto-Tellez M; Tan P
J Proteome Res; 2008 Apr; 7(4):1518-28. PubMed ID: 18318472
[TBL] [Abstract][Full Text] [Related]
7. Morphoproteomic and pharmacoproteomic correlates in hormone-receptor-negative breast carcinoma cell lines.
Brown RE; Lun M; Prichard JW; Blasick TM; Zhang PL
Ann Clin Lab Sci; 2004; 34(3):251-62. PubMed ID: 15487699
[TBL] [Abstract][Full Text] [Related]
8. Differential expression and regulation of bone morphogenetic protein 7 in breast cancer.
Schwalbe M; Sänger J; Eggers R; Naumann A; Schmidt A; Höffken K; Clement JH
Int J Oncol; 2003 Jul; 23(1):89-95. PubMed ID: 12792780
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometry: a new approach for the molecular profiling of breast cancer.
Lostumbo A; Mehta D; Setty S; Nunez R
Exp Mol Pathol; 2006 Feb; 80(1):46-53. PubMed ID: 16271361
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
12. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
[TBL] [Abstract][Full Text] [Related]
13. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
14. A novel breast cancer cell line initially established from pleural effusion: evolution towards a more aggressive phenotype.
Schmidt M; Khan A; Schmidt AM; Heinze B; Hack E; Waltenberger J; Kreienberg R
Int J Oncol; 2007 Mar; 30(3):565-72. PubMed ID: 17273757
[TBL] [Abstract][Full Text] [Related]
15. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells.
Willipinski-Stapelfeldt B; Riethdorf S; Assmann V; Woelfle U; Rau T; Sauter G; Heukeshoven J; Pantel K
Clin Cancer Res; 2005 Nov; 11(22):8006-14. PubMed ID: 16299229
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
[TBL] [Abstract][Full Text] [Related]
17. CD109 expression in basal-like breast carcinoma.
Hasegawa M; Moritani S; Murakumo Y; Sato T; Hagiwara S; Suzuki C; Mii S; Jijiwa M; Enomoto A; Asai N; Ichihara S; Takahashi M
Pathol Int; 2008 May; 58(5):288-94. PubMed ID: 18429827
[TBL] [Abstract][Full Text] [Related]
18. Micro-fluidic chip platform for the characterization of breast cancer cells using aptamer-assisted immunohistochemistry.
Yeong Won J; Choi JW; Min J
Biosens Bioelectron; 2013 Feb; 40(1):161-6. PubMed ID: 22841444
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
20. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES
Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
